The monoclonal antibody Emicizumab prophylactic administration [28] has emerged as an alternative to factor replacement in managing severe hemophilia A. However, this might not be possible with limited resources in the near future; hence developing countries such as Pakistan should focus on optimizing FVIII regimens tailored according to our patient population. Here, F8 is linked to hemophilia A.